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Abstract  
Potent HIV neutralizing antibodies are critical for vaccination and viral reservoir control. 
High levels of neutralizing antibodies characterize HIV-2 infection, a naturally-occurring 
model of attenuated HIV disease with low to undectable viremia. We found that HIV-2-
specific antibody potency increased in direct association with the loss of both switched 
and unswitched memory B-cells in untreated HIV-2 infection. Thus, HIV antibody 
affinity maturation is linked to memory B-cell exhaustion even in reduced viremia 
settings.    
 
Research letter 
The specificity and variability of antibodies (Abs) is achieved by affinity maturation 
through somatic hypermutation and clonal selection. This process proceeds for weeks 
after acute infections or vaccination. There is much debate about the mutation levels and 
chronic antigen exposure needed to generate broadly neutralizing antibodies (bNAbs) 
against HIV-1 [1]. In adults, bNAbs usually take two to four years to develop and are 
associated with high viremia and low CD4 T-cell counts [2-7]. In contrast to HIV-1, most 
HIV-2 infected patients develop potent bNAb responses [8-12]. In addition, HIV-2 
infection usually courses with undetectable viral load and very slow rate of CD4 T-cell 
decline even in the absence of antiviral treatment [13, 14]. Therefore understanding the 
generation of broad and potent neutralizing antibodies in this unique model of naturally-
occurring control of viremia is relevant for the vaccine field.  
We aim to investigate the relationship between memory B-cells and NAb response in 
untreated HIV-2 infected adults. Previously we have shown that these patients featured 
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contraction of the memory B-cell compartment in direct association with the degree of 
CD4 T-cell depletion and markers of immune activation, suggesting the occurrence of 
lymphoid tissue disruption [15]. Here we asked how this finding relates with HIV-2-
specific Abs.  
We analysed the NAb response in 27 untreated HIV-2 infected patients, included in a 
previous report [15]. Twenty-one patients (78%) had undetectable viral load (detectable 
in 6 patients, ranging from 1189 to 13627 RNA copies/ml), and 20 (74%) had CD4 T-cell 
counts above 350 cells/µl (median 568, range 52-1511 cells/µl). Informed consent for 
blood collection and participation in the study was obtained from all participants, under 
the approval of the Ethical Board of the Faculty of Medicine, University of Lisbon. HIV-
2 viremia was quantified by RT-PCR (detection threshold: 40 RNA copies/ml), as 
previously described [16, 17]. The neutralizing activity was analysed in plasma against a 
panel of four heterologous primary CCR5-tropic isolates (03PTHCC6, 03PTHCC12, 
03PTHCC19, 03PTHSM2). Origin and characterization of these isolates, and their 
sensitivity to IgG NAbs, have been described elsewhere [10, 18, 19]. A luciferase 
reporter gene assay in TZM-bl cells was used, as described previously [20, 21]. 
Additionally, binding antibodies against HIV-2 envelope glycoproteins gp125 (C2V3C3 
region) and gp36 were quantified in samples from a subset of the patients using an 
ELISA-HIV2 assay as previously described [15, 22]. Memory B-cell populations were 
assessed based on the expression of CD27 and surface IgD by flow cytometry, with class-
switched memory B-cells defined as CD19+CD27+IgDneg and unswitched memory B-
cells as CD19+CD27+IgDpos, as described previously [15]. Serum B-cell activating factor 
(BAFF) levels were quantified by ELISA as previously described [15]. Statistical 
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analysis was performed with GraphPad Prism 5.0 (Graph Pad Software, Prism 5, version 
5.04, 2010). P values were 2-tailed and significance was defined as P <0.05. Linear 
regression was performed and Spearman correlation coefficients were computed. 
All patients produced Nabs against the panel of four primary R5 isolates, with a median 
reciprocal log10IC50 neutralization titer of 2.89 (interquartile ranged 2.76-3.18). NAb 
potency and breadth were directly associated (N=27, Spearman rank, r=0.4916, 
P=0.0092; Supplemental Digital Content 1, http://links.lww.com/QAD/B170). Moreover, 
Nab potency and breadth were not associated with CD4+ T-cell counts (N=27, Spearman 
rank, r=-0.1902, P=0.3419 and r=-0.0325, P=0.8723, respectively). Nab potency has 
generally not been associated with the number of CD4 T-cells in previous HIV-2 studies 
[9, 23], except when patients representing the full spectrum of disease were analysed 
[10].  
NAb potency increased in direct association with the increase in C2V3C3-specific 
binding Abs (N=12, Spearman rank, r=0.7250, P=0.0098) (Supplemental Digital Content 
2 – blue, http://links.lww.com/QAD/B170). However, no association was found between 
NAb potency and gp36-specific binding Abs (N=12, Spearman rank, r=0.4483, 
P=0.1446) (Supplemental Digital Content 2 – black, http://links.lww.com/QAD/B170). Our 
findings confirm the presence of broad and potent NAbs targeting the C2V3C3-envelope 
region during chronic HIV-2 infection, as described previously [10].  
NAb potency was found to increase significantly with the loss of switched (N=27, 
Spearman rank, r=-0.6436, P=0.0003) and unswitched (N=27, Spearman rank, r=-4162, 
P=0.031) memory B-cell populations (Figure 1 – top and bottom, respectively). In 
accordance with the association between NAbs and binding Abs, the loss of both 
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switched and unswitched memory B-cell populations was directly correlated with the 
increase in C2V3C3-specific binding Abs (N=12, Spearman rank, r=-0.7622, P=0.0055 
and r=-0.6434, P=0.0278, respectively; Supplemental Digital Content 3, 
http://links.lww.com/QAD/B170). No association was found between switched and 
unswitched memory B-cell populations and gp36-specific binding Abs (N=12, Spearman 
rank, r=-0.5455, P=0.0708 and r=-0.2517, P=0.4303, respectively; Supplemental Digital 
Content 3, http://links.lww.com/QAD/B170). No association was found between Nab titers 
and BAFF levels (N=11, Spearman rank, r=0.1455, P=0.6731; Supplemental Digital 
Content 4, http://links.lww.com/QAD/B170), despite the previous report of BAFF increase 
in parallel with B cell disturbances in HIV-2 infected individuals [15]. 
To our knowledge, this is the first study addressing the relationship between NAb 
responses in HIV-2-infected patients and memory B-cell disturbances. In spite of the 
limitations imposed by the number of patients and sample availability that only allowed 
to test four viral isolates, we were able to reveal a strong direct association between 
memory B-cell exhaustion and the generation of NAbs as well as C2V3C3 binding Abs. 
These findings suggest that, multiple rounds of HIV-2 infection are important for the 
generation of highly specific Abs, and that this happens at the expense of the memory B-
cell pool. The lack of hypogammaglobulinemia [15] is likely due to the persistence of 
long-lived plasma cells has shown in other clinical settings [24]. Although the levels of 
plasma viral load were reduced in HIV-2 infection even in the absence of ART, we have 
shown that the extent of viral reservoirs is similar in HIV-2 and HIV-1 individuals [17, 
25]. Moreover, HIV-2 has been shown to infect and induce cytopathicity in lymphoid 
tissues [26], supporting that there is contained local viral replication [27]. The prolonged 
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time of infection that characterizes HIV-2 pathogenesis, favours the continuous exposure 
to envelope antigens (either present in plasma viruses or bound to the surface of infected 
cells) and persistent immune activation [25]. This setting is ideal for the generation of 
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Figure 1 – Association between neutralizing antibodies and memory B-cells. Spearman's 
rank correlation coefficient was used to assess associations between neutralizing antibody 
titers and frequency of switched (CD27+IgDneg – top) and unswitched (CD27+IgDpos – 
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